. The HOPE4MCI study: AGB101 treatment slows progressionof entorhinal cortex atrophy in APOE ε4 non-carriers with mildcognitive impairment due to Alzheimer’s disease. Alzheimer's & Dementia, 17 May 2024

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. AGB101